Key Points
- Insider sale: Director David Solomon Williams III sold 5,000 shares on Dec. 4 at an average price of $9.43 for $47,150, leaving him with 45,045 shares — a 9.99% reduction in his stake (≈$424,774 remaining value).
- Recent results: AdaptHealth reported EPS of $0.19 (missing the $0.24 consensus) while revenue of $820.31M beat expectations; the stock opened at $9.42 with a market cap of about $1.28B and a 1‑year range of $7.11–$11.63.
- Market/analyst posture: Institutional investors own 82.67% of AHCO, analysts' consensus is a "Moderate Buy" with a $13.60 price target, though individual ratings are mixed (upgrades and downgrades reported).
AdaptHealth Corp. (NASDAQ:AHCO - Get Free Report) Director David Solomon Williams III sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $9.43, for a total value of $47,150.00. Following the completion of the transaction, the director directly owned 45,045 shares in the company, valued at approximately $424,774.35. This represents a 9.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
AdaptHealth Trading Up 0.4%
Shares of AHCO opened at $9.42 on Friday. The firm has a market cap of $1.28 billion, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 1.38 and a beta of 1.77. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.08 and a quick ratio of 0.86. AdaptHealth Corp. has a 1 year low of $7.11 and a 1 year high of $11.63. The company has a 50 day simple moving average of $9.32 and a two-hundred day simple moving average of $9.21.
AdaptHealth (NASDAQ:AHCO - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.05). AdaptHealth had a return on equity of 4.85% and a net margin of 2.53%.The company had revenue of $820.31 million during the quarter, compared to analysts' expectations of $799.62 million. During the same period last year, the firm posted $0.15 EPS. AdaptHealth's quarterly revenue was up 1.8% compared to the same quarter last year. On average, equities analysts expect that AdaptHealth Corp. will post 0.88 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in AHCO. AlphaQuest LLC increased its stake in AdaptHealth by 275.7% during the second quarter. AlphaQuest LLC now owns 3,941 shares of the company's stock worth $37,000 after acquiring an additional 2,892 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of AdaptHealth by 87.6% in the 2nd quarter. Assetmark Inc. now owns 5,529 shares of the company's stock worth $52,000 after purchasing an additional 2,581 shares during the period. Brooklyn Investment Group boosted its holdings in shares of AdaptHealth by 531.8% in the 1st quarter. Brooklyn Investment Group now owns 7,563 shares of the company's stock worth $82,000 after purchasing an additional 6,366 shares during the period. Tower Research Capital LLC TRC increased its position in shares of AdaptHealth by 318.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company's stock valued at $90,000 after purchasing an additional 7,297 shares during the last quarter. Finally, Tidal Investments LLC purchased a new stake in AdaptHealth during the 2nd quarter valued at $96,000. Institutional investors own 82.67% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have commented on AHCO. Canaccord Genuity Group increased their price objective on shares of AdaptHealth from $14.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, November 6th. Zacks Research downgraded AdaptHealth from a "hold" rating to a "strong sell" rating in a research report on Friday, September 19th. Weiss Ratings restated a "hold (c-)" rating on shares of AdaptHealth in a report on Tuesday. Finally, Wall Street Zen downgraded AdaptHealth from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $13.60.
Read Our Latest Stock Analysis on AHCO
AdaptHealth Company Profile
(
Get Free Report)
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
